You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. PA-21-260: PHS 2021-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

    Release Date: 07-08-2021Open Date: 08-06-2021 Due Dates: Multiple Close Date: 04-06-2022

    The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, also known as America's Seed Fund, are one of the largest sources of early-stage capital for technology commercialization in the United States. These programs enable US-owned and operated small businesses to conduct research and development that has a strong potential for commercialization. Nation ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. RFA-DA-22-023: Advancing Validated Drug Targets for Substance Use Disorders (R43/R44- Clinical Trial Not Allowed)

    Release Date: 07-29-2021Open Date: 01-18-2022Due Date: 02-18-2022Close Date: 02-19-2022

    Background Substance use disorders (SUDs) affect people from all walks of life and all age groups. These illnesses are common, recurrent, and often serious, but they are treatable, and many people recover. SUDs occur when the recurrent use of drugs causes clinically significant impairment, including health problems, disability, and failure to meet major responsibilities at work, school, or home. ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. RFA-TR-21-010: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)

    Release Date: 01-13-2021Open Date: 03-13-2021 Due Dates: Multiple Close Date: 01-13-2022

    A. Overview While there are thousands of rare diseases, the number of underlying etiologies is much smaller. Moreover, many disease etiologies underly multiple traditional diseases. This is most readily seen for rare monogenic diseases, where the most common etiologies include premature termination codons, protein misfolding, and abnormal RNA splicing. Other examples of rare disease shared molecu ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. RFA-ES-21-008: Innovative Approaches for Improving Environmental Health Literacy (R43/R44 Clinical Trial Not Allowed)

    Release Date: 08-12-2021Open Date: 10-10-2021Due Date: 11-10-2021Close Date: 11-11-2021

    Background The National Institute of Environmental Health Sciences (NIEHS) continues to support innovative and diverse partnerships to bring environmental health science concepts to various audiences with the goal of improving their environmental health literacy (https://www.niehs.nih.gov/about/strategicplan/2018-2023_theme2/index.cfm). At the most fundamental level, environmental health literacy ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. NIH/NCATS 022: Technological Development and Validation of Remote Measures for Use in Clinical Trials in Individuals with Rare Diseases

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    (Fast-Track proposals will not be accepted. Phase II information is provided only for informational purposes to assist Phase I offerors with their long-term strategic planning.) Number of anticipated awards: 1 to 4 Budget (total costs, per award): Phase I: $325,000 for 9 months; Phase II: $2,000,000 for 2 years It is strongly suggested that proposals adhere to the above budget amounts and project ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. NIH/NCI 430: DEVELOPMENT OF SENOTHERAPEUTIC AGENTS FOR CANCER TREATMENT

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will be accepted. Direct-to-Phase II proposals will be accepted. Number of anticipated awards: 3-5 Budget (total costs, per award): Phase I: up to $400,000 for up to 12 months Phase II: up to $2,000,000 for up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Summary Age is a well-recognized risk factor for cancer development; and ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. NIH/NCI 431: CANCER TREATMENT TECHNOLOGIES FOR LOW-RESOURCE SETTINGS

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track Proposal will be accepted Direct-to-Phase II proposal will be accepted Number of Anticipated Awards: 3-5 Budget (total costs, per award): Phase I: up to $400,000 for 12 months Phase II: up to $2,000,000 for 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Summary Cancer is a leading cause of premature death in low-resource settings globally. N ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. NIH/NCI 432: SYNTHETIC BIOLOGY GENE CIRCUITS FOR CANCER THERAPY

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will NOT be accepted. Direct Phase II proposal will be accepted Number of anticipated awards: 3 - 5 Budget (total costs, per award): Phase I: up to $400,000 for up to 12 months Phase II: up to $2,000,000 for up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Summary Gene therapy has come of age over the past few years. One of the ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. NIH/NCI 433: DEVELOPING UNBIASED MEDICAL TECHNOLOGIES TO REDUCE DISPARITIES IN CANCER OUTCOMES

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will be accepted. Direct-to-Phase II proposals will be accepted. Number of anticipated awards: 3-5 Budget (total costs, per award): Phase I: up to $400,000 for up to 12 months Phase II: up to $2,000,000 for up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Summary There is an urgent need to spur innovation in developing unbiased ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. NIH/NCI 434: ULTRA-FAST DOSE RATE (FLASH) RADIATION DETECTORS AND SAFETY SYSTEMS

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will be accepted. Direct-to-Phase II proposals will be accepted. Number of anticipated awards: 2-3 Budget (total costs, per award): Phase I: up to $400,000 for up to 12 months Page 74 Phase II: up to $2,000,000 for up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Summary An important development in the field of radiation oncolo ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government